Lipocine Presents Phase 3 Clinical Data for Oral Brexanolone (LPCN 1154) in Postpartum Depression

On May 26, 2026, Lipocine Inc. (LPCN) announced the presentation of Phase 3 clinical data for its lead candidate, LPCN 1154, at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami Beach, FL. LPCN 1154 is a novel oral formulation of brexanolone, a neuroactive steroid being developed for the treatment of postpartum depression (PPD). The presentation and accompanying poster detailed results from a placebo-controlled Phase 3 trial evaluating the efficacy and safety of the oral candidate. While the summary text of the 8-K focuses on the event of the presentation, the inclusion of Phase 3 placebo-controlled data at a major medical meeting typically indicates the company is moving forward with its regulatory strategy for the oral neuroactive steroid. The company furnished the full presentation and poster as exhibits to the filing to provide detailed clinical outcomes to investors and the medical community.